A. E. van der Bijl

989 total citations
17 papers, 660 citations indexed

About

A. E. van der Bijl is a scholar working on Rheumatology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, A. E. van der Bijl has authored 17 papers receiving a total of 660 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Rheumatology, 5 papers in Pathology and Forensic Medicine and 4 papers in Genetics. Recurrent topics in A. E. van der Bijl's work include Rheumatoid Arthritis Research and Therapies (8 papers), Systemic Lupus Erythematosus Research (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). A. E. van der Bijl is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (8 papers), Systemic Lupus Erythematosus Research (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). A. E. van der Bijl collaborates with scholars based in Netherlands, Germany and United States. A. E. van der Bijl's co-authors include Frank P. Kroon, Leo G. Visser, L. B. S. Gelinck, T. Huizinga, G.F. Rimmelzwaan, R. A. van Hogezand, Mart A F J van de Laar, W.E.P. Beyer, Cornelia F Allaart and H. H. Kuper and has published in prestigious journals such as Clinical Orthopaedics and Related Research, Annals of the Rheumatic Diseases and Vaccine.

In The Last Decade

A. E. van der Bijl

17 papers receiving 639 citations

Peers

Countries citing papers authored by A. E. van der Bijl

Since Specialization

Citations

This map shows the geographic impact of A. E. van der Bijl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. E. van der Bijl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. E. van der Bijl more than expected).

Fields of papers citing papers by A. E. van der Bijl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. E. van der Bijl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. E. van der Bijl. The network helps show where A. E. van der Bijl may publish in the future.

Co-authorship network of co-authors of A. E. van der Bijl

This figure shows the co-authorship network connecting the top 25 collaborators of A. E. van der Bijl. A scholar is included among the top collaborators of A. E. van der Bijl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. E. van der Bijl. A. E. van der Bijl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Long-term disease and patient-reported outcomes of a continuous treat-to-target approach in patients with early rheumatoid arthritis in daily clinical practice 2018 ·Clinical Rheumatology ·(unknown), (unknown), Harald E. Vonkeman, Peter M. ten Klooster, A. E. van der Bijl, Mart A F J van de Laar	41
2	Sustained Beneficial Effects of a Protocolized Treat‐to‐Target Strategy in Very Early Rheumatoid Arthritis: Three‐Year Results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort 2013 ·Arthritis Care & Research ·M. Vermeer, H. H. Kuper, Hein J. Bernelot Moens, K.W. Drossaers-Bakker, A. E. van der Bijl, Piet L. C. M. van Riel, Mart A F J van de Laar	64
3	The new ACR / EULAR Definition of Remission in Rheumatoid Arthritis: Is the Patient Global Assessment Criterion too strict? 2012 ·Annals of the Rheumatic Diseases ·M. Vermeer, (unknown), A. E. van der Bijl, (unknown), Marcel D. Posthumus, H.L.M. Brus, P.L. van Riel, Mart A F J van de Laar	4
4	The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion 2012 ·Lara D. Veeken ·Maarten H. Vermeer, H. H. Kuper, A. E. van der Bijl, (unknown), Marcel D. Posthumus, H.L.M. Brus, P. L. C. M. van Riel, Mart A F J van de Laar	45
5	Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible 2009 ·Vaccine ·L. B. S. Gelinck, Bart J. F. van den Bemt, Erik W.A. Marijt, A. E. van der Bijl, Leo G. Visser, (unknown), G.F. Rimmelzwaan, Frank P. Kroon	55
6	Brain involvement in rheumatoid arthritis: A magnetic resonance spectroscopy study 2009 ·Arthritis & Rheumatism ·Bart J. Emmer, A. E. van der Bijl, T. Huizinga, Ferdinand C. Breedveld, Stefan C. A. Steens, Gerlof P. T. Bosma, Mark A. van Buchem, Jeroen van der Grond	21
7	Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: A clinical randomized trial 2009 ·Arthritis Care & Research ·A. E. van der Bijl, Y K Onno Teng, M. van Oosterhout, F. C. Breedveld, Cornelia F Allaart, T. Huizinga	15
8	An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status 2008 ·Clinical Rheumatology ·A. E. van der Bijl, Ferdinand C. Breedveld, Christian Antoni, Joachim R. Kalden, S. Kary, Gerd R Burmester, Christina Beckmann, Kristina Unnebrink, H. Küpper	69
9	Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine 2008 ·Vaccine ·L. B. S. Gelinck, A. E. van der Bijl, Leo G. Visser, T. Huizinga, R. A. van Hogezand, Ger T. Rijkers, Frank P. Kroon	44
10	Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis 2007 ·Arthritis & Rheumatism ·A. E. van der Bijl, Y P M Goekoop-Ruiterman, Jeska K de Vries‐Bouwstra, S. ten Wolde, K. H. Han, M V van Krugten, Cornelia F Allaart, F. C. Breedveld, Ben A. C. Dijkmans	92
11	The effect of anti-tumour necrosis factor α treatment on the antibody response to influenza vaccination 2007 ·Annals of the Rheumatic Diseases ·L. B. S. Gelinck, A. E. van der Bijl, W.E.P. Beyer, Leo G. Visser, T. Huizinga, R. A. van Hogezand, G.F. Rimmelzwaan, Frank P. Kroon	141
12	Advanced magnetic resonance imaging of the brain in patients treated with TNF-alpha blocking agents. 2007 ·PubMed ·A. E. van der Bijl, Bart J. Emmer, FC Breedveld, Huub A.M. Middelkoop, Caroline K. Jurgens, Mark A. van Buchem, T. Huizinga, Jeroen van der Grond	7
13	Movement Disorders Induced by Gastrointestinal Drugs: Two Paediatric Cases 2006 ·Neuropediatrics ·(unknown), Y. A. Hekster, A. E. van der Bijl, Jan J. Rotteveel	5
14	A nasal squamous cell carcinoma complicated by a paraneoplastic syndrome consisting of a myositis and anti-Jo-1 autoantibodies 2005 ·European Journal of Internal Medicine ·A. E. van der Bijl, A. Edo Meinders, Sjoerd G. van Duinen, J.T. Tamsma	4
15	Rheumatoid vasculitis treated with infliximab. 2005 ·PubMed ·A. E. van der Bijl, Cornelia F Allaart, Jeroen P.P. van Vugt, Sjoerd G. van Duinen, Ferdinand C. Breedveld	18
16	Accuracy of the Jamshidi Trocar Biopsy in the Diagnosis of Bone Tumors 1997 ·Clinical Orthopaedics and Related Research ·A. E. van der Bijl, A. H. M. Taminiau, John J. Hermans, H Beerman, Pancras C.W. Hogendoorn	23
17	Unique Combination of an Ovarian Gonadoblastoma, Dysgerminoma, and Mucinous Cystadenoma in a Patient with Turnerʼs Syndrome: A Cytogenetic and Molecular Analysis 1994 ·International Journal of Gynecological Pathology ·A. E. van der Bijl, Gert Jan Fleuren, Gemma G. Kenter, Daphne de Jong	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact